All Stories

  1. Pro-dopaminergic pharmacological interventions for anhedonia in depression: a living systematic review and network meta-analysis of human and animal studies
  2. Developing treatments for cerebral small vessel disease: a scoping review of licensed interventions for potential repurposing
  3. A How-to Guide for Research Improvement within Research-Performing Institutions
  4. Mechanisms through which exercise reduces symptom severity and/or functional impairment in posttraumatic stress disorder (PTSD): Protocol for a living systematic review of human and non-human studies
  5. Building a synthesis-ready research ecosystem: fostering collaboration and open science to accelerate biomedical translation
  6. The therapeutic potential of exercise in post-traumatic stress disorder and its underlying mechanisms: A living systematic review of human and non-human studies
  7. Mechanisms through which exercise reduces symptom severity and/or functional impairment in posttraumatic stress disorder (PTSD): Protocol for a living systematic review of human and non-human studies
  8. Muscarinic receptor agonists and positive allosteric modulators in animal models of psychosis: protocol for a systematic review and meta-analysis
  9. Testing the usefulness of a quality system in preclinical research
  10. Triangulating evidence from the GALENOS living systematic review on trace amine-associated receptor 1 (TAAR1) agonists in psychosis
  11. Developing treatments for cerebral small vessel disease: a scoping review of licensed interventions for potential repurposing
  12. Safety and efficacy of memantine and trazodone versus placebo for motor neuron disease (MND SMART): stage two interim analysis from the first cycle of a phase 3, multiarm, multistage, randomised, adaptive platform trial
  13. A Systematic Online Living Evidence Summary of experimental Alzheimer’s disease research
  14. Strategy for developing data standards in support of automation of Systematic Reviews
  15. Analysis of animal-to-human translation shows that only 5% of animal-tested therapeutic interventions obtain regulatory approval for human applications
  16. Trace amine-associated receptor 1 (TAAR1) agonism for psychosis: a living systematic review and meta-analysis of human and non-human data
  17. Understanding the provenance and quality of methods is essential for responsible reuse of FAIR data
  18. Genetically modified animals as models of neurodevelopmental conditions: A review of systematic review reporting quality
  19. Prevention of infections and fever to improve outcome in older patients with acute stroke (PRECIOUS): a randomised, open, phase III, multifactorial, clinical trial with blinded outcome assessment
  20. Evaluating artificial intelligence software for delineating hemorrhage extent on CT brain imaging in stroke
  21. Genetically-modified animals as models of neurodevelopmental conditions: a review of systematic review reporting quality
  22. Mechanisms through which exercise reduces symptom severity and/or functional impairment in posttraumatic stress disorder (PTSD): Protocol for a living systematic review of human and non-human studies
  23. Pro-dopaminergic pharmacological interventions for anhedonia in depression: protocol for a living systematic review of human and non-human studies
  24. From data deluge to publomics: How AI can transform animal research
  25. Blood biomarker changes following therapeutic hypothermia in ischemic stroke
  26. A Systematic Online Living Evidence Summary of experimental Alzheimer’s disease research
  27. The Automated Systematic Search Deduplicator (ASySD): a rapid, open-source, interoperable tool to remove duplicate citations in biomedical systematic reviews
  28. The UK Reproducibility Network: A progress report
  29. Trace amine-associated receptor 1 (TAAR1) agonists for psychosis: protocol for a living systematic review and meta-analysis of human and non-human studies.
  30. New living evidence resource of human and non-human studies for early intervention and research prioritisation in anxiety, depression and psychosis
  31. Identifying a research agenda for postgraduate taught education in the UK: lessons from a machine learning facilitated systematic scoping review
  32. Accuracy of artificial intelligence software for CT angiography in stroke
  33. Systematic online living evidence summaries: emerging tools to accelerate evidence synthesis
  34. Designing, conducting, and reporting reproducible animal experiments
  35. Advanced methods and implementations for the meta-analyses of animal models: Current practices and future recommendations
  36. Screening for in vitro systematic reviews: a comparison of screening methods and training of a machine learning classifier
  37. EFFECTS OF GALACTO-OLIGOSACCHARIDE PREBIOTICS IN THE FLINDERS SENSITIVE LINE RAT MODEL OF DEPRESSION ON BEHAVIOURAL OUTCOMES
  38. Frequency and Phenotype Associations of Rare Variants in 5 Monogenic Cerebral Small Vessel Disease Genes in 200,000 UK Biobank Participants
  39. PICO entity extraction for preclinical animal literature
  40. The EQIPD framework for rigor in the design, conduct, analysis and documentation of animal experiments
  41. Screening for in vitro systematic reviews: a comparison of screening methods and training of a machine learning classifier
  42. Systematic Online Living Evidence Summaries: emerging tools to accelerate evidence synthesis
  43. Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease
  44. Meta-analysis on reporting practices as a source of heterogeneity in in vitro cancer research
  45. Effectiveness of biomaterial-based combination strategies for spinal cord repair – a systematic review and meta-analysis of preclinical literature
  46. Improving the reproducibility and integrity of research: what can different stakeholders contribute?
  47. A Systematic Approach to Identify Neuroprotective Interventions for Motor Neuron Disease
  48. MDAR (Material, Design, Analysis Reporting): A Modular Framework for Transparent Reporting in the Life Sciences
  49. What has preclinical systematic review ever done for us?
  50. The reproducibility debate is an opportunity, not a crisis
  51. Improving research quality: the view from the UK Reproducibility Network institutional leads for research improvement
  52. From grassroots to global: A blueprint for building a reproducibility network
  53. Risk of bias assessment in preclinical literature using natural language processing
  54. Using median survival in meta-analysis of experimental time-to-event data
  55. PICO Entity Extraction For Preclinical Animal Literature
  56. Meta-analysis on reporting practices as a source of heterogeneity in in vitro cancer research
  57. Technological advances in preclinical meta-research
  58. Building a Systematic Online Living Evidence Summary of COVID-19 Research
  59. Red blood cell transfusion in animal models of acute brain injuries: a systematic review protocol
  60. Risk of Bias Assessment in Preclinical Literature using Natural Language Processing
  61. Introduction to the EQIPD quality system
  62. Meta-analysis of variation suggests that embracing variability improves both replicability and generalizability in preclinical research
  63. Epidemiology and reporting characteristics of preclinical systematic reviews
  64. The Automated Systematic Search Deduplicator (ASySD): a rapid, open-source, interoperable tool to remove duplicate citations in biomedical systematic reviews
  65. The MDAR (Materials Design Analysis Reporting) Framework for transparent reporting in the life sciences
  66. Regulatory delays in a multinational clinical stroke trial
  67. Systematic review and meta-analysis of cannabinoids, cannabis-based medicines, and endocannabinoid system modulators tested for antinociceptive effects in animal models of injury-related or pathological persistent pain
  68. Development and uptake of an online systematic review platform: the early years of the CAMARADES Systematic Review Facility (SyRF)
  69. Results of a randomised controlled trial comparing two different incentives to improve survey response rates
  70. Using Median Survival in Meta-analysis of Experimental Time-to-event Data
  71. Protocol for an analysis of in vivo reporting standards by journal, institution and funder
  72. Comparison of commonly used methods in random effects meta-analysis: application to preclinical data in drug discovery research
  73. Can harmonisation of outcomes bridge the translation gap for pre-clinical research? A systematic review of outcomes measured in mouse models of type 2 diabetes
  74. Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data
  75. Feasibility of reporting results of large randomised controlled trials to participants: experience from the Fluoxetine Or Control Under Supervision (FOCUS) trial
  76. Effects of dietary fat manipulation on cognition in mice and rats: protocol for a systematic review and meta-analysisEffects of dietary fat manipulation on cognition in mice and rats: protocol for a systematic review and meta-analysis
  77. Red Blood Cell Transfusion in Animal Models of Acute Brain Injuries: A Systematic Review Protocol
  78. Embrace heterogeneity to improve reproducibility: A perspective from meta-analysis of variation in preclinical research
  79. The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days
  80. Identifying and understanding factors that affect the translation of therapies from the laboratory to patients: a study protocol
  81. The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days
  82. A Systematic Review and Meta-Analysis of Hypothermia in Experimental Traumatic Brain Injury: Why Have Promising Animal Studies Not Been Replicated in Pragmatic Clinical Trials?
  83. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study
  84. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research
  85. Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2.0
  86. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research
  87. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research*
  88. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research
  89. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research
  90. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research
  91. Identifying and understanding factors that affect the translation of therapies from the laboratory to patients: a study protocol
  92. Real-world Independent Testing of e-ASPECTS Software (RITeS): statistical analysis plan
  93. Systematic review of guidelines for internal validity in the design, conduct and analysis of preclinical biomedical experiments involving laboratory animals
  94. FAIR SCI Ahead: The Evolution of the Open Data Commons for Pre-Clinical Spinal Cord Injury Research
  95. UK consensus on pre-clinical vascular cognitive impairment functional outcomes assessment: Questionnaire and workshop proceedings
  96. Introducing our series: research synthesis and meta-research in biology
  97. Framework for advancing rigorous research
  98. Meta-analysis of targeted temperature management in animal models of cardiac arrest
  99. Research Culture and Reproducibility
  100. Ischaemic stroke
  101. Compressive Pressure Versus Time in Cauda Equina Syndrome
  102. The ARRIVE guidelines 2019: updated guidelines for reporting animal research
  103. Reporting animal research: Explanation and Elaboration for the ARRIVE guidelines 2019
  104. Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial
  105. Extending thrombolysis to 4·5–9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data
  106. A randomised controlled trial of an Intervention to Improve Compliance with the ARRIVE guidelines (IICARus)
  107. Outcome heterogeneity and bias in acute experimental spinal cord injury
  108. Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial
  109. Animal models of chemotherapy-induced peripheral neuropathy: A machine-assisted systematic review and meta-analysis
  110. Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke
  111. Administration of galacto-oligosaccharide prebiotics in the Flinders Sensitive Line animal model of depression
  112. Protocol for a systematic review and meta-analysis of data from preclinical studies employing forced swimming test: an update
  113. Towards minimum reporting standards for life scientists
  114. Therapeutic hypothermia for acute ischaemic stroke. Results of a European multicentre, randomised, phase III clinical trial
  115. A European initiative to unclog pipeline for new medicines
  116. The development and evaluation of an online application to assist in the extraction of data from graphs for use in systematic reviews
  117. Reader response: Evaluating depression and suicidality in tetrabenazine users with Huntington disease
  118. Did a change in Nature journals’ editorial policy for life sciences research improve reporting?
  119. Warlow's Stroke
  120. The development and evaluation of an online application to assist in the extraction of data from graphs for use in systematic reviews
  121. Machine learning algorithms for systematic review: reducing workload in a preclinical review of animal studies and reducing human screening error
  122. Identifying stroke therapeutics from preclinical models: A protocol for a novel application of network meta-analysis
  123. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial
  124. Design of Meta-Analysis Studies
  125. Targeting mitochondrial dysfunction in amyotrophic lateral sclerosis: a systematic review and meta-analysis
  126. Reproducibility and Rigor in Animal-Based Research
  127. The development and evaluation of an online application to assist in the extraction of data from graphs for use in systematic reviews
  128. Potentially serious incidental findings on brain and body magnetic resonance imaging of apparently asymptomatic adults: systematic review and meta-analysis
  129. Protocol for a systematic review of guidelines for rigour in the design, conduct and analysis of biomedical experiments involving laboratory animals
  130. The reproducibility opportunity
  131. NXY-059, a Failed Stroke Neuroprotectant, Offers No Protection to Stem Cell-Derived Human Neurons
  132. A randomised controlled trial of an Intervention to Improve Compliance with the ARRIVE guidelines (IICARus)
  133. PRECIOUS: PREvention of Complications to Improve OUtcome in elderly patients with acute Stroke. Rationale and design of a randomised, open, phase III, clinical trial with blinded outcome assessment
  134. Small vessels, dementia and chronic diseases – molecular mechanisms and pathophysiology
  135. Effect size and statistical power in the rodent fear conditioning literature – A systematic review
  136. Animal models of chemotherapy-induced peripheral neuropathy: a machine-assisted systematic review and meta-analysis A comprehensive summary of the field to inform robust experimental design
  137. Automation of citation screening in pre-clinical systematic reviews
  138. The REstart or STop Antithrombotics Randomised Trial (RESTART) after stroke due to intracerebral haemorrhage: study protocol for a randomised controlled trial
  139. Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial
  140. The use of text-mining and machine learning algorithms in systematic reviews: reducing workload in preclinical biomedical sciences and reducing human screening error
  141. A systematic review and meta-analysis of topoisomerase inhibition in pre-clinical glioma models
  142. Estimating the statistical performance of different approaches to meta-analysis of data from animal studies in identifying the impact of aspects of study design
  143. Facilitating healthcare decisions by assessing the certainty in the evidence from preclinical animal studies
  144. Learning lessons from MVA85A, a failed booster vaccine for BCG
  145. Transparency in the reporting of in vivo pre-clinical pain research: The relevance and implications of the ARRIVE (Animal Research: Reporting In Vivo Experiments) guidelines
  146. Correction: D-galactose-induced brain ageing model: A systematic review and meta-analysis on cognitive outcomes and oxidative stress indices
  147. Statistical analysis plan for the EuroHYP-1 trial: European multicentre, randomised, phase III clinical trial of the therapeutic hypothermia plus best medical treatment versus best medical treatment alone for acute ischaemic stroke
  148. Identification and characterization of outcome measures reported in animal models of epilepsy: Protocol for a systematic review of the literature-A TASK2 report of the AES/ILAE Translational Task Force of the ILAE
  149. Living systematic reviews: 2. Combining human and machine effort
  150. Living systematic reviews: 3. Statistical methods for updating meta-analyses
  151. Living systematic reviews: 4. Living guideline recommendations
  152. Risk of bias reporting in the recent animal focal cerebral ischaemia literature
  153. Marine-derived n-3 fatty acids therapy for stroke
  154. The Experimental Design Assistant
  155. The Experimental Design Assistant
  156. Findings of a retrospective, controlled cohort study of the impact of a change in Nature journals' editorial policy for life sciences research on the completeness of reporting study design and execution
  157. Standardized mean differences cause funnel plot distortion in publication bias assessments
  158. Living systematic review: 1. Introduction—the why, what, when, and how
  159. D-galactose-induced brain ageing model: A systematic review and meta-analysis on cognitive outcomes and oxidative stress indices
  160. Development of a psychological intervention for fatigue after stroke
  161. The IMPROVE Guidelines (Ischaemia Models: Procedural Refinements Of in Vivo Experiments)
  162. Alpha Calcitonin Gene-Related Peptide Increases Cerebral Vessel Diameter in Animal Models of Subarachnoid Hemorrhage: A Systematic Review and Meta-analysis
  163. Increasing value and reducing waste in stroke research
  164. Conjugal amyotrophic lateral sclerosis: a case report from Scotland
  165. Effect size and statistical power in the rodent fear conditioning literature - a systematic review
  166. Evolution of ischemic damage and behavioural deficit over 6 months after MCAo in the rat: Selecting the optimal outcomes and statistical power for multi-centre preclinical trials
  167. No publication without confirmation
  168. Hypothermia revisited: Impact of ischaemic duration and between experiment variability
  169. Improving our understanding of thein vivomodelling of psychotic disorders: A protocol for a systematic review and meta‐analysis
  170. Protocol for a systematic review and meta-analysis of experimental models of amyotrophic lateral sclerosis
  171. Understanding in vivo modelling of depression in non-human animals: a systematic review protocol
  172. Protocols for laboratory research
  173. Evaluating mesenchymal stem cell therapy for sepsis with preclinical meta-analyses prior to initiating a first-in-human trial
  174. The Devil Is in the Details: Incomplete Reporting in Preclinical Animal Research
  175. Study protocol - A systematic review and meta-analysis of hypothermia in experimental traumatic brain injury: Why have promising animal studies not been replicated in pragmatic clinical trials?
  176. Multicenter Evaluation of Geometric Accuracy of MRI Protocols Used in Experimental Stroke
  177. Systematic Review and Meta-Analysis of the Efficacy of Interleukin-1 Receptor Antagonist in Animal Models of Stroke: an Update
  178. Protocol for a systematic review of effect sizes and statistical power in the rodent fear conditioning literature
  179. The Efficacy of Trastuzumab in Animal Models of Breast Cancer: A Systematic Review and Meta-Analysis
  180. From a mouse: systematic analysis reveals limitations of experiments testing interventions in Alzheimer's disease mouse models
  181. A proposed framework for the systematic review and integrated assessment (SYRINA) of endocrine disrupting chemicals
  182. Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets
  183. Olfactory Ensheathing Cell Transplantation in Experimental Spinal Cord Injury: Effect size and Reporting Bias of 62 Experimental Treatments: A Systematic Review and Meta-Analysis
  184. SWIFT-Review: a text-mining workbench for systematic review
  185. Protocol for a retrospective, controlled cohort study of the impact of a change in Nature journals’ editorial policy for life sciences research on the completeness of reporting study design and execution
  186. Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF
  187. Cardiac Stem Cell Treatment in Myocardial InfarctionNovelty and Significance
  188. Corrigendum to ‘Meta-analysis of data from animal studies: A practical guide’
  189. How to Avoid Bumping into the Translational Roadblock
  190. AVERT 2 (a very early rehabilitation trial, a very effective reproductive trigger): retrospective observational analysis of the number of babies born to trial staff
  191. Effect of alteplase on the CT hyperdense artery sign and outcome after ischemic stroke
  192. Correction: Risk of Bias in Reports of In Vivo Research: A Focus for Improvement
  193. Informatics: Make sense of health data
  194. How individual participant data meta-analyses have influenced trial design, conduct, and analysis
  195. Translational failure of anti-inflammatory compounds for myocardial infarction: a meta-analysis of large animal models
  196. Risk of Bias in Reports of In Vivo Research: A Focus for Improvement
  197. The Clots in Legs Or sTockings after Stroke (CLOTS) 3 trial: a randomised controlled trial to determine whether or not intermittent pneumatic compression reduces the risk of post-stroke deep vein thrombosis and to estimate its cost-effectiveness
  198. Consent for Brain Tissue Donation after Intracerebral Haemorrhage: A Community-Based Study
  199. Exploring threats to generalisability in a large international rehabilitation trial (AVERT)
  200. Interventions for post-stroke fatigue
  201. Efficacy and safety of very early mobilisation within 24 h of stroke onset (AVERT): a randomised controlled trial
  202. Effect of Endothelin Receptor Antagonists on Clinically Relevant Outcomes after Experimental Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis
  203. Prof Benchie and Dr Athena-A modern tragedy…
  204. Increasing value and reducing waste in animal models of rheumatological disease
  205. Drug Repurposing: A Systematic Approach to Evaluate Candidate Oral Neuroprotective Interventions for Secondary Progressive Multiple Sclerosis
  206. Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): a randomised trial
  207. Experimental design and reporting standards for improving the internal validity of pre-clinical studies in the field of pain: Consensus of the IMI-Europain consortium
  208. Uptake of systematic reviews and meta-analyses based on individual participant data in clinical practice guidelines: descriptive study
  209. Magnetic Resonance Imaging in Experimental Stroke and Comparison With Histology
  210. Model of Understanding Fatigue After Stroke
  211. Influence of Intracerebral Hemorrhage Location on Incidence, Characteristics, and Outcome
  212. A systematic review and meta‐analysis of gene therapy in animal models of cerebral glioma: why did promise not translate to human therapy?
  213. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis
  214. Effect of intermittent pneumatic compression on disability, living circumstances, quality of life, and hospital costs after stroke: secondary analyses from CLOTS 3, a randomised trial
  215. Similar Effect of Autologous and Allogeneic Cell Therapy for Ischemic Heart Disease: Systematic Review and Meta-Analysis of Large Animal Studies
  216. Efficacy of Antidepressants in Animal Models of Ischemic Stroke: A Systematic Review and Meta-Analysis
  217. Preclinical research: Design animal studies better
  218. Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embol...
  219. EuroHYP-1: European Multicenter, Randomized, Phase III Clinical Trial of Therapeutic Hypothermia plus Best Medical Treatment vs. Best Medical Treatment Alone for Acute Ischemic Stroke
  220. End-of-life decisions in patients with severe acute brain injury
  221. Psychological Associations of Poststroke Fatigue: A Systematic Review and Meta-Analysis
  222. Using Animal Models to Understand Cancer Pain in Humans
  223. Outcome After Conservative Management or Intervention for Unruptured Brain Arteriovenous Malformations
  224. Clopidogrel Plus Aspirin Versus Warfarin in Patients With Stroke and Aortic Arch Plaques
  225. Research: increasing value, reducing waste – Authors' reply
  226. Systematic Reviews and Meta-Analysis of Preclinical Studies: Why Perform Them and How to Appraise Them Critically
  227. Exercise Reduces Infarct Volume and Facilitates Neurobehavioral Recovery
  228. Therapeutic Hypothermia and the Risk of Infection
  229. A (mini) pill for stroke?
  230. Some Salt with Your Statin, Professor?
  231. Hypothermia Protects Human Neurons
  232. Systematic Review and Meta-Analysis of Interventions Tested in Animal Models of Lacunar Stroke
  233. Meta-analysis of data from animal studies: A practical guide
  234. Increasing value and reducing waste in research design, conduct, and analysis
  235. Increasing value and reducing waste in biomedical research regulation and management
  236. Effect and Reporting Bias of RhoA/ROCK-Blockade Intervention on Locomotor Recovery After Spinal Cord Injury
  237. Biomedical research: increasing value, reducing waste
  238. Efficacy and safety of mesenchymal stromal cells in preclinical models of acute lung injury: a systematic review protocol
  239. Stem Cell Transplantation in Traumatic Spinal Cord Injury: A Systematic Review and Meta-Analysis of Animal Studies
  240. Edoxaban versus Warfarin in Patients with Atrial Fibrillation
  241. Bringing rigour to translational medicine
  242. Edaravone Improves Functional and Structural Outcomes in Animal Models of Focal Cerebral Ischemia: A Systematic Review
  243. Meta-Analysis of Pre-Clinical Studies of Early Decompression in Acute Spinal Cord Injury: A Battle of Time and Pressure
  244. Systematic Review and Meta-Analysis of Therapeutic Hypothermia in Animal Models of Spinal Cord Injury
  245. Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial
  246. Evaluation of Excess Significance Bias in Animal Studies of Neurological Diseases
  247. Hypertension and Experimental Stroke Therapies
  248. Animal models of bone cancer pain: Systematic review and meta-analyses
  249. Systematic review and stratified meta-analysis of the efficacy of RhoA and Rho kinase inhibitors in animal models of ischaemic stroke
  250. Prevalence and natural history of pain in adults with multiple sclerosis: Systematic review and meta-analysis
  251. A Concerted Appeal for International Cooperation in Preclinical Stroke Research
  252. Evidence-based Translational Medicine
  253. Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted?
  254. Role of multidetector computed tomography in the diagnosis and management of patients attending the rapid access chest pain clinic, The Scottish computed tomography of the heart (SCOT-HEART) trial: study protocol for randomized controlled trial
  255. A call for transparent reporting to optimize the predictive value of preclinical research
  256. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial
  257. The Benefit of Hypothermia in Experimental Ischemic Stroke is Not Affected by Pethidine
  258. Improving the Efficiency of the Development of Drugs for Stroke
  259. Translational Research
  260. Stem Cell-Based Therapy for Experimental Stroke: A Systematic Review and Meta-Analysis
  261. Voltage-gated potassium channel antibody-related encephalopathy: a case which may extend the documented phenotype of this condition
  262. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial
  263. Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial
  264. Pharmacologic Reduction of Angiographic Vasospasm in Experimental Subarachnoid Hemorrhage: Systematic Review and Meta-Analysis
  265. Vorapaxar in the Secondary Prevention of Atherothrombotic Events
  266. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF
  267. Untreated clinical course of cerebral cavernous malformations: a prospective, population-based cohort study
  268. Evaluation of Combination Therapy in Animal Models of Cerebral Ischemia
  269. Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited
  270. The timing, extent, progression and regression of deep vein thrombosis in immobile stroke patients: observational data from the CLOTS multicenter randomized trials
  271. Preclinical studies of human disease: Time to take methodological quality seriously
  272. Why animal research needs to improve
  273. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
  274. Sodium and chloride channelopathies with myositis: Coincidence or connection?
  275. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial
  276. Dopamine agonists in animal models of Parkinson’s disease: A systematic review and meta-analysis
  277. Not Tonight, Darling, I Might Get a Headache
  278. Systematic Survey of the Design, Statistical Analysis, and Reporting of Studies Published in the 2008 Volume of the Journal of Cerebral Blood Flow and Metabolism
  279. Treatment of intracerebral hemorrhage in animal models: Meta-analysis
  280. Systematic Survey of the Design, Statistical Analysis, and Reporting of Studies Published in the 2008 Volume of theJournal of Cerebral Blood Flow and Metabolism
  281. Animal models of neurological disease: are there any babies in the bathwater?
  282. Hypothermia for Stroke: Call to Action 2010
  283. Preclinical Drug Evaluation for Combination Therapy in Acute Stroke Using Systematic Review, Meta-Analysis, and Subsequent Experimental Testing
  284. B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial
  285. Improving the translational hit of experimental treatments in multiple sclerosis
  286. Factors Affecting the Apparent Efficacy and Safety of Tissue Plasminogen Activator in Thrombotic Occlusion Models of Stroke: Systematic Review and Meta-Analysis
  287. Different Strokes for Different Folks: The Rich Diversity of Animal Models of Focal Cerebral Ischemia
  288. Comment on "Detection of an Infectious Retrovirus, XMRV, in Blood Cells of Patients with Chronic Fatigue Syndrome"
  289. Therapeutic Hypothermia for Acute Ischemic Stroke: Ready to Start Large Randomized Trials?
  290. Publication Bias in Reports of Animal Stroke Studies Leads to Major Overstatement of Efficacy
  291. Can Animal Models of Disease Reliably Inform Human Studies?
  292. How to Avoid Bumping into the Translational Roadblock
  293. A Systematic Review and Meta-Analysis of Erythropoietin in Experimental Stroke
  294. Emulating Multicentre Clinical Stroke Trials: A New Paradigm for Studying Novel Interventions in Experimental Models of Stroke
  295. Bacterial meningitis associated with a complex ischiorectal abscess
  296. Stroke research at a road block: the streets from adversity should be paved with meta-analysis and good laboratory practice
  297. Systematic Review and Stratified Meta-analysis of the Efficacy of Interleukin-1 Receptor Antagonist in Animal Models of Stroke
  298. Scope of Preclinical Testing Versus Quality Control Within Experiments
  299. Injury-induced mineralocorticoid receptor expression involves differential promoter usage: A novel role for the rat MRβ variant
  300. Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial
  301. Reprint: Good Laboratory Practice: Preventing Introduction of Bias at the Bench
  302. Stroke Therapy Academic Industry Roundtable (STAIR) Recommendations for Extended Window Acute Stroke Therapy Trials
  303. Surgical decompression for space-occupying cerebral infarction (the Hemicraniectomy After Middle Cerebral Artery infarction with Life-threatening Edema Trial [HAMLET]): a multicentre, open, randomised trial
  304. Mineralocorticoid receptor mRNA expression is increased in human hippocampus following brief cerebral ischaemia
  305. Update of the Stroke Therapy Academic Industry Roundtable Preclinical Recommendations
  306. REPRINT: Good Laboratory Practice: Preventing Introduction of Bias at the Bench
  307. Effect of hyperthermia and anoxia on glucocorticoid and mineralocorticoid receptor expression in neonatal rat hippocampus
  308. Rationale and Design of a Randomized, Double-Blind, Parallel-Group Study of Terutroban 30 mg/day versus Aspirin 100 mg/day in Stroke Patients: The Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients wi...
  309. General anaesthesia versus local anaesthesia for carotid surgery (GALA): a multicentre, randomised controlled trial
  310. The Future of Restorative Neurosciences in Stroke: Driving the Translational Research Pipeline From Basic Science to Rehabilitation of People After Stroke
  311. What is the translational efficacy of chemotherapeutic drug research in neuro-oncology? A systematic review and meta-analysis of the efficacy of BCNU and CCNU in animal models of glioma
  312. Reprint: Good Laboratory Practice: Preventing Introduction of Bias at the Bench
  313. Secondary prevention of stroke – Authors' reply
  314. Good Laboratory Practice: Preventing Introduction of Bias at the Bench
  315. Evidence for the Efficacy of NXY-059 in Experimental Focal Cerebral Ischaemia Is Confounded by Study Quality
  316. Stroke
  317. Predicting outcome in hyper-acute stroke: validation of a prognostic model in the Third International Stroke Trial (IST3)
  318. Outcome after interventional or conservative management of unruptured brain arteriovenous malformations: a prospective, population-based cohort study
  319. Empirical Evidence of Bias in the Design of Experimental Stroke Studies: A Metaepidemiologic Approach
  320. A Systematic Review and Meta-Analysis of the Efficacy of Piracetam and Piracetam-Like Compounds in Experimental Stroke
  321. How can we improve the pre-clinical development of drugs for stroke?
  322. Vanishing diplopia: a problem case
  323. Hypothermia in animal models of acute ischaemic stroke: a systematic review and meta-analysis
  324. Forebrain mineralocorticoid receptor overexpression enhances memory, reduces anxiety and attenuates neuronal loss in cerebral ischaemia
  325. Systematic Review and Meta-Analysis of the Efficacy of Tirilazad in Experimental Stroke
  326. Comparison of treatment effects between animal experiments and clinical trials: systematic review
  327. Hemicraniectomy after middle cerebral artery infarction with life-threatening Edema trial (HAMLET). Protocol for a randomised controlled trial of decompressive surgery in space-occupying hemispheric infarction
  328. Aortic Arch Atheroma
  329. 1,026 Experimental treatments in acute stroke
  330. Greater Incidence of Both Fatal and Nonfatal Strokes in Disadvantaged Areas: The Northeast Melbourne Stroke Incidence Study
  331. Current Issues in the Treatment of Acute Posterior Circulation Stroke
  332. Epilepsy update
  333. Surveying the literature from animal experiments: Systematic review and meta-analysis are important contributions
  334. Neuro-oncology for non-oncologists
  335. Overexpression of the mineralocorticoid receptor protects against injury in PC12 cells
  336. Systematic Review and Metaanalysis of the Efficacy of FK506 in Experimental Stroke
  337. Gender and deprivation and rates of referral and thereby admission to a national neurorehabilitation service
  338. Systematic review and meta-analysis of the efficacy of melatonin in experimental stroke
  339. Results of a Multicentre, Randomised Controlled Trial of Intra-Arterial Urokinase in the Treatment of Acute Posterior Circulation Ischaemic Stroke
  340. MicroRNA – Taking Regulation of Protein Synthesis to Another Level
  341. Nicotinamide Attenuates Focal Ischemic Brain Injury: Meta-Analysis or Mechanism of Protection
  342. Atheroma of the aortic arch: an important and poorly recognised factor in the aetiology of stroke
  343. Pooling of Animal Experimental Data Reveals Influence of Study Design and Publication Bias
  344. Media Watch
  345. Atheroma of the aortic arch: the missing link in the secondary prevention of stroke?
  346. Inequalities in the incidence and management of, and outcome from, neurological diseases in older people
  347. Mineralocorticoid receptor expression and increased survival following neuronal injury
  348. Effect of deprivation on time to hospital in acute stroke
  349. Reduced NMDA-induced apoptosis in neurons lacking ataxia telangiectasia mutated protein
  350. PubMed: http://www.pubmed.org
  351. Effect of deprivation and gender on the incidence and management of acute brain disorders
  352. What's a good doctor and how do you make one?
  353. Nitric-oxide-synthase-mediated cyclic guanosine monophosphate production in neonatal rat cerebellar prisms is resistant to calcineurin inhibition
  354. Serum withdrawal causes apoptosis in SHSY 5Y cells
  355. Caspase 6 activity initiates caspase 3 activation in cerebellar granule cell apoptosis
  356. The effect of tumour associated epilepsy on performance/handicap scales used in cerebral glioma
  357. Ischaemic heart disease and cholesterol There's more to heart disease than cholesterol